Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

LANGEPHARM ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   4.8% 4.2% 10.1% 21.4% 14.1% 9.8% 23.6% 23.6%   Credit score (0-100)   47 50 26 4 14 24 3 4   Credit rating   BBB BBB BB B BB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   197 205 184 -33.0 -11.8 -8.5 0.0 0.0   EBITDA   107 85.3 184 -33.0 -11.8 -8.5 0.0 0.0   EBIT   107 85.3 184 -33.0 -11.8 -8.5 0.0 0.0   Pre-tax profit (PTP)   133.6 114.7 207.2 -33.0 -12.0 -8.5 0.0 0.0   Net earnings   104.1 89.5 161.6 -25.7 -9.4 -6.6 0.0 0.0   Pre-tax profit without non-rec. items   134 115 207 -33.0 -12.0 -8.5 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   852 941 1,103 839 830 823 0.0 0.0   Interest-bearing liabilities   0.0 0.0 0.0 0.0 66.2 66.2 0.0 0.0   Balance sheet total (assets)   988 1,075 1,257 941 896 899 0.0 0.0   Net Debt   -171 -263 -453 -411 -101 -100 -0.0 -0.0     See the entire balance sheet 1000.0 Volume  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   197 205 184 -33.0 -11.8 -8.5 0.0 0.0   Gross profit growth   53.0% 4.3% -10.4% 0.0% 64.2% 28.3% 0.0% 0.0%   Employees   1 1 0 0 0 0 0 0   Employee growth %   0.0% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   988 1,075 1,257 941 896 899 0 0   Balance sheet change%   12.9% 8.9% 16.9% -25.1% -4.8% 0.4% -100.0% 0.0%   Added value   106.9 85.3 184.0 -33.0 -11.8 -8.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 -1.0 -2.0 -3.0 0.0 0.0   1000.0 Profitability  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   54.3% 41.6% 100.0% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   14.7% 11.4% 18.3% -3.0% -1.3% -0.9% 0.0% 0.0%   ROI %   17.1% 13.1% 20.9% -3.4% -1.4% -0.9% 0.0% 0.0%   ROE %   13.0% 10.0% 15.8% -2.6% -1.1% -0.8% 0.0% 0.0%   1000.0 Solidity  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Equity ratio %   86.3% 87.5% 87.8% 89.1% 92.6% 91.5% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -159.6% -308.0% -246.0% 1,246.1% 852.3% 1,181.1% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 8.0% 8.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0% 0.0%   1000.0 Liquidity  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Quick Ratio   6.5 7.2 8.2 9.2 13.5 11.8 0.0 0.0   Current Ratio   6.5 7.2 8.2 9.2 13.5 11.8 0.0 0.0   Cash and cash equivalent   170.5 262.8 452.7 410.9 166.8 166.2 0.0 0.0   1000.0 Capital use efficiency  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   750.6 835.9 1,103.0 839.0 829.7 823.1 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023e N/A 2024e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   107 85 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   107 85 0 0 0 0 0 0   EBIT / employee   107 85 0 0 0 0 0 0   Net earnings / employee   104 89 0 0 0 0 0 0